POR CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative

Por um escritor misterioso
Last updated 20 setembro 2024
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
CVM-1118 (foslinanib) is a phosphoric ester compound selected from 2-phenyl-4-quinolone derivatives. The NCI 60 cancer panel screening showed CVM-1125, the major active metabolite of CVM-1118, to exhibit growth inhibitory and cytotoxic effects at nanomolar range. CVM-1118 possesses multiple bioactivities, including inducing cellular apoptosis, cell cycle arrest at G2/M, as well as inhibiting vasculogenic mimicry (VM) formation. The TNF receptor associated protein 1 (TRAP1) was identified as the binding target of CVM-1125 using nematic protein organization technique (NPOT) interactome analysis. Further studies demonstrated CVM-1125 reduced the protein level of TRAP1 and impeded its downstream signaling by reduction of cellular succinate levels and destabilization of HIF-1α. The pharmacogenomic biomarkers associated with CVM-1118 were also examined by Whole Genome CRISPR Knock-Out Screening. Two hits (STK11 and NF2) were confirmed with higher sensitivity to the drug in cell knock-down experiments. Biological assays indicate that the mechanism of action of CVM-1118 is via targeting TRAP1 to induce mitochondrial apoptosis, suppress tumor cell growth, and inhibit vasculogenic mimicry formation. Most importantly, the loss-of-function mutations of STK11 and NF2 are potential biomarkers of CVM-1118 which can be applied in the selection of cancer patients for CVM-1118 treatment. CVM-1118 is currently in its Phase 2a clinical development.
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Combined drug treatment inhibits the nuclear localization of HSF1 and
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
POR Potential predictors for CDX2 expression loss and mismatch repair deficiency in colorectal cancer
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Tumor cell vascular mimicry: Novel targeting opportunity in melanoma. - Abstract - Europe PMC
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
HSP 75 Antibody (TR1) SCBT - Santa Cruz Biotechnology
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
TRAP1 activity in tumor cell mitochondria. (A) TRAP1 inhibits oxidative
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Vascular mimicry drives metastatic progression. a, Serial sections of a
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Tumor cell vascular mimicry: Novel targeting opportunity in melanoma. - Abstract - Europe PMC
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
POR Three-dimensional analysis of perineural invasion in extrahepatic cholangiocarcinoma using tissue clearing
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Lkb1 (Qiagen), Bioz
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Cellular requirements of mitochondrial Hsp90-directed tumor cell
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
Full article: Developing our knowledge of the quinolone scaffold and its value to anticancer drug design
POR  CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative
TRAP1 Knockdown Inhibits In Vitro and In Vivo Neoplastic Transformation

© 2014-2024 digiamaz.ir. All rights reserved.